$MOLN
MOLECULAR PARTNERS AG
CIK:0001745114|SEC Filings
Consolidated Statement of Cash Flows - CHF (SFr) SFr in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Statement of cash flows [abstract] | |||
| Net result attributable to shareholders | SFr (61,651) | SFr (54,043) | SFr (61,984) |
| Adjustments for: | |||
| Depreciation and amortization | 2,144 | 2,369 | 2,420 |
| Social security and tax paid on behalf of employees on shares vested under the PSU and RSU program | (325) | 0 | 0 |
| Share-based compensation costs | 4,419 | 4,105 | 5,207 |
| Change in employee benefits | (546) | (670) | 535 |
| Income tax | 2 | 2 | 0 |
| Financial income | (1,522) | (7,214) | (4,279) |
| Financial expenses | 5,047 | 38 | 5,155 |
| Changes in working capital: | |||
| Change in other current assets | 335 | 237 | 1,424 |
| Change in trade and other receivables | 485 | (347) | (933) |
| Change in trade and other payables | 65 | 524 | (812) |
| Change in contract liability | 0 | (4,333) | (5,713) |
| Change in accrued expenses | 343 | 161 | 45 |
| Exchange (loss) gain on working capital positions | (18) | (39) | (21) |
| Interest paid | (18) | (26) | (34) |
| Other financial expense | (15) | (12) | (15) |
| Net cash (used in) from operating activities | (51,257) | (59,248) | (59,005) |
| Proceeds from investments in short-term time deposits | 137,814 | 277,015 | 319,443 |
| Investments in short-term time deposits | (66,278) | (240,045) | (277,825) |
| Acquisition of property, plant and equipment | (714) | (705) | (575) |
| Acquisition of intangible assets | 0 | (18) | (233) |
| Interest received | 1,727 | 4,239 | 3,827 |
| Net cash from (used in) investing activities | 72,549 | 40,486 | 44,637 |
| Proceeds from issuance of new shares | 0 | 17,342 | 0 |
| Proceeds from vesting under the LTI plans | 62 | 0 | 0 |
| Transaction costs on issue of shares | 0 | (1,741) | 0 |
| Proceeds from issuance of shares under LTI plans | 1 | 40 | 31 |
| Payment of lease liabilities | (1,212) | (1,208) | (1,198) |
| Net cash from (used in) financing activities | (1,149) | 14,433 | (1,167) |
| Exchange (loss) gain on cash positions | (1,364) | 894 | (5,102) |
| Net increase (decrease) in cash and cash equivalents | 18,779 | (3,435) | (20,637) |
| Cash and cash equivalents at January 1 | 63,874 | 67,309 | 87,946 |
| Cash and cash equivalents at December 31 | SFr 82,653 | SFr 63,874 | SFr 67,309 |
Consolidated Statement of Financial Position - CHF (SFr) SFr in Thousands |
Dec. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|
| Assets | ||
| Property, plant and equipment | SFr 5,229 | SFr 4,198 |
| Intangible assets | 2 | 49 |
| Total non-current assets | 5,231 | 4,247 |
| Short-term time deposits | 10,405 | 85,565 |
| Other current assets | 1,985 | 2,525 |
| Trade and other receivables | 1,834 | 2,317 |
| Cash and cash equivalents | 82,653 | 63,874 |
| Total current assets | 96,876 | 154,281 |
| Total assets | 102,107 | 158,528 |
| Shareholders' equity and liabilities | ||
| Share capital | 4,037 | 4,036 |
| Additional paid-in capital | 389,179 | 384,875 |
| Treasury share reserve | (1,129) | (981) |
| Cumulative losses | (311,753) | (246,293) |
| Total shareholders' equity | 80,334 | 141,637 |
| Trade and other payables | 160 | 0 |
| Lease liability | 2,438 | 1,227 |
| Employee benefits | 8,147 | 4,879 |
| Total non-current liabilities | 10,746 | 6,106 |
| Trade and other payables | 1,767 | 1,859 |
| Accrued expenses | 8,055 | 7,709 |
| Lease liability | 1,206 | 1,217 |
| Total current liabilities | 11,027 | 10,785 |
| Total liabilities | 21,772 | 16,891 |
| Total shareholders' equity and liabilities | SFr 102,107 | SFr 158,528 |